Evidence map›Paper›PMID 32929084›Full record

ArticleNature communications2020

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells.

Demet Candas-Green, Bowen Xie, Jie Huang, Ming Fan, Aijun Wang, Cheikh Menaa, Yanhong Zhang, Lu Zhang, Di Jing, Soheila Azghadi and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 144 citations in OpenAlex.

  1. Trial
  2. Article
  3. The immunology of human breast cancer.Nature reviews. Immunology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 9 institutions in 2 countries.

Demet Candas-Green *Department of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Bowen Xie *Department of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Jie HuangDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0003-0381-1549
Ming FanDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Aijun WangDepartment of Surgery, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.ORCID http://orcid.org/0000-0002-2985-3627
Cheikh MenaaDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Yanhong ZhangDepartment of Pathology, Kaiser Permanente Medical Center Vallejo and Vacaville, Vallejo, CA, USA.
Lu ZhangDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Di JingDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Soheila AzghadiDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Weibing ZhouDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Lin LiuDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Nian JiangDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Tao LiDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Tianyi GaoDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Colleen SweeneyDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Rulong ShenDepartment of Pathology, Ohio State University, Columbus, OH, USA.
Tzu-Yin LinDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Chong-Xian PanNCI-Designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.
Omer M OzpiskinDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Gayle WoloschakDepartment of Radiation Oncology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
David J GrdinaDepartment of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA.
Andrew T VaughanDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
Ji Ming WangChemoattractant Receptor and Signal Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Shuli XiaDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.
Arta M MonjazebDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA.
William J MurphyNCI-Designated Comprehensive Cancer Center, University of California Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0002-2793-401X
Lun-Quan SunCenter for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hong-Wu ChenDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA.
Jian Jian LiDepartment of Radiation Oncology, University of California Davis, Sacramento, CA, USA. jijli@ucdavis.edu.ORCID http://orcid.org/0000-0003-3694-9675
University of California, Davis · USCentral South University · CNUniversity of Chicago · USJohns Hopkins University · USKaiser Permanente Vallejo Medical Center · USNational Cancer Institute · USNorthwestern University · USThe Ohio State University · USUniversity of California System · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
Therapeutic targeting of orphan NR in ER-negative breast cancerR01CA224900 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEN, HONGWU · 2019 to 2023
$2.1M
Mitochondrial bioenergetics is associated with aggressive breast cancer growthR01CA213830 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, JIAN JIAN · 2017 to 2021
$1.8M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA213830NCI NIH HHS R01 CA224900
6 · The paper itself

Abstract

Although the efficacy of cancer radiotherapy (RT) can be enhanced by targeted immunotherapy, the immunosuppressive factors induced by radiation on tumor cells remain to be identified. Here, we report that CD47-mediated anti-phagocytosis is concurrently upregulated with HER2 in radioresistant breast cancer (BC) cells and RT-treated mouse syngeneic BC. Co-expression of both receptors is more frequently detected in recurrent BC patients with poor prognosis. CD47 is upregulated preferentially in HER2-expressing cells, and blocking CD47 or HER2 reduces both receptors with diminished clonogenicity and augmented phagocytosis. CRISPR-mediated CD47 and HER2 dual knockouts not only inhibit clonogenicity but also enhance macrophage-mediated attack. Dual antibody of both receptors synergizes with RT in control of syngeneic mouse breast tumor. These results provide the evidence that aggressive behavior of radioresistant BC is caused by CD47-mediated anti-phagocytosis conjugated with HER2-prompted proliferation. Dual blockade of CD47 and HER2 is suggested to eliminate resistant cancer cells in BC radiotherapy.

Indexed as

Radiation ToleranceAnimalsBreast NeoplasmsCD47 AntigenCell ProliferationClone CellsErb-b2 Receptor Tyrosine KinasesFemaleHumansMacrophagesMCF-7 CellsMiceModels, BiologicalNF-kappa BPhagocytosisSignal TransductionCD47 AntigenERBB2 protein, humanErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesNF-kappa B

Identifiers

PMID32929084
PMCPMC7490264
OpenAlexW3086673837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.